VERA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vera Therapeutics, Inc (VERA) does not present a strong buying opportunity at this time for a beginner investor with a long-term strategy. While the stock has potential upside based on analyst ratings and the market's large opportunity for its product, the technical indicators, financial performance, and lack of strong trading signals suggest waiting for a clearer entry point.
The MACD is negatively expanding (-0.311), indicating bearish momentum. RSI is at 24.858, which is neutral but leaning towards oversold territory. Moving averages are converging, showing no clear trend. The stock is trading near its S1 support level (38.886), with resistance at 42.354. This suggests limited immediate upside.
Analysts have upgraded the stock with high price targets (e.g., Wolfe Research at $88, H.C. Wainwright at $110). The market opportunity for atacicept remains significant, with peak sales potential of $2.2B in IgAN alone.
The MACD and technical indicators suggest bearish momentum. Financial performance shows no revenue growth, and the company is still operating at a significant net loss (-$91M in Q4 2025). No recent news or congress trading data to act as a catalyst.
In Q4 2025, revenue remained at $0 with no growth. Net income improved YoY but is still negative (-$91M). EPS improved to -1.39, but the company remains unprofitable. Gross margin remains at 0%.
Analysts are bullish, with Wolfe Research upgrading the stock to Outperform and setting a price target of $88. H.C. Wainwright raised its target to $110, citing priority review for atacicept. BofA reiterated a Buy rating, citing underappreciated peak sales potential.
